Sign inSubscribe

target directory

amg 355 pembrolizumab clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT06131398
Source recordAI-normalized

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

AI analysis

Indication: Advanced Solid Tumors

Modality: small molecule

Target: AMG 355, Pembrolizumab

Sponsor: Amgen

Source URL: ClinicalTrials.gov

Source updated: May 28, 2026

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: AMG 355, Pembrolizumab

View original source fields

Condition raw: Advanced Solid Tumors

Condition normalized: Advanced Solid Tumors

Modality raw: small molecule

Modality normalized: small molecule

Target raw: AMG 355, Pembrolizumab

Target normalized: AMG 355, Pembrolizumab

Open report